New inhaled drug AGMB-447 tested for lung scarring disease
Disease control
Completed
This study tests an inhaled drug called AGMB-447 in healthy volunteers and people with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs. The main goal is to check safety and how the body processes the drug. 143 participants will receive either the drug or a pla…
Phase: PHASE1 • Sponsor: Agomab Spain S.L. • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC